Utility of “smart” inhaler and suppression of fractional exhaled nitric oxide (FeNO): does it make a difference to patient outcomes?
Y. See (Hull, United Kingdom), E. Chow (Hull, United Kingdom), M. Crooks (Hull, United Kingdom), M. Robinson (Hull, United Kingdom), K. Watkins (Hull, United Kingdom), F. Turner (Hull, United Kingdom), J. Thompson (Hull, United Kingdom), S. Faruqi (Hull, United Kingdom), E. Chow (Hull, United Kingdom)
Source: International Congress 2022 – Chronic airway diseases and infections: management and prevalence
 
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Y. See (Hull, United Kingdom), E. Chow (Hull, United Kingdom), M. Crooks (Hull, United Kingdom), M. Robinson (Hull, United Kingdom), K. Watkins (Hull, United Kingdom), F. Turner (Hull, United Kingdom), J. Thompson (Hull, United Kingdom), S. Faruqi (Hull, United Kingdom), E. Chow (Hull, United Kingdom). Utility of “smart” inhaler and suppression of fractional exhaled nitric oxide (FeNO): does it make a difference to patient outcomes?. 2406
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|